Track Bristol-Myers Squibb Company — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Bristol-Myers Squibb Company BMYS.VI · Stock Open Bristol-Myers Squibb Company in new tab

56.09 EUR
P/E
13.91
EPS
3.99
Yield
3.89%
P/B
5.79
ROE
46.60
Beta
0.23
Loading chart...
Key Metrics
P/E13.91
EPS3.99
Book Value9.59
Price to Book5.79
Debt/Equity201.86
% Insiders0.097%
Growth
Revenue Growth0.06%
Earnings Growth1.53%
Dividend
Dividend Yield3.89%
Annual dividends2.18 EUR
Ex-Div. DateJuly 2, 2026
Payout55.29%
5y avg Yield4.06%

DCF Valuation

Tweak assumptions to recompute fair value for Bristol-Myers Squibb Company (BMYS.VI)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Bristol-Myers Squibb Company Logo Bristol-Myers Squibb Company Analysis (BMYS.VI)

United States Health Care Official Website Stock

Is Bristol-Myers Squibb Company a good investment? Bristol-Myers Squibb Company (BMYS.VI) is currently trading at 56.09 EUR.

In terms of valuation, the stock trades at a P/E ratio of 13.91. This relatively low multiple may signal that Bristol-Myers Squibb Company is undervalued compared to historical market norms.

For income investors, Bristol-Myers Squibb Company pays a dividend yield of 3.89%. With a payout ratio of 55%, the dividend appears sustainable.

Investor FAQ

Does Bristol-Myers Squibb Company pay a dividend?

Yes, it pays an annual dividend of 2.18 EUR (3.89% yield).

What asset class is Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company is classified as a Stock.

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Trades
Dividend Yield
3.89%
5y avg 4.06%
Annual Dividends
2.18EUR
Next Ex. Div Date
July 2, 2026
Payout Ratio
55.29%
Dividend History paid per year (EUR)
Historical Dividends
Year Total Dividends
▸2027
1.73 EUR
July 5, 2027 (estimated) 0.5897
April 2, 2027 (estimated) 0.5745
Jan. 4, 2027 (estimated) 0.5661
▸2026
2.19 EUR
Oct. 5, 2026 (estimated) 0.5571
July 2, 2026 0.5507
April 2, 2026 0.5458
Jan. 2, 2026 0.5371
▸2025
2.21 EUR
Oct. 3, 2025 0.5286
July 3, 2025 0.5286
April 4, 2025 0.5286
Jan. 3, 2025 0.6200
▸2024
2.40 EUR
Oct. 4, 2024 0.6000
July 5, 2024 0.6000
April 4, 2024 0.6000
Jan. 4, 2024 0.6000
▸2023
2.28 EUR
Oct. 5, 2023 0.5700
July 6, 2023 0.5700
April 6, 2023 0.5700
Jan. 5, 2023 0.5700
▸2022
2.16 EUR
Oct. 6, 2022 0.5400
June 30, 2022 0.5400
March 31, 2022 0.5400
Jan. 6, 2022 0.5400
▸2021
1.47 EUR
Sept. 30, 2021 0.4900
July 1, 2021 0.4900
March 31, 2021 0.4900
▸2020
2.29 EUR
Dec. 30, 2020 0.4900
Oct. 1, 2020 0.4500
July 2, 2020 0.4500
April 2, 2020 0.4500
Jan. 2, 2020 0.4500
▸2019
0.82 EUR
Oct. 3, 2019 0.4100
July 3, 2019 0.4100
Upcoming Dividends
Name Payment Date Status Amount
Bristol-Myers Squibb Company Jul 02, 2026 0.550746 EUR
Bristol-Myers Squibb Company Apr 02, 2026 0.545769 EUR
Bristol-Myers Squibb Company Jan 02, 2026 0.537075 EUR
Bristol-Myers Squibb Company Oct 03, 2025 0.52855 EUR
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion